CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a biopharmaceutical company, has recently presented promising data regarding PALI-2108, a colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug, at the American College of Gastroenterology's Annual Scientific Meeting. The data from translational studies showcased the bioactivation of PALI-2108 in ex vivo conditions, suggesting potential advantages over existing PDE4 inhibitors for treating ulcerative colitis (UC).
The studies evaluated the conversion of PALI-2108 to its active form in stool samples from both healthy individuals and UC patients, achieving a high conversion rate. Additionally, the active form, PALI-0008, exhibited significant inhibition of tumor necrosis factor-alpha (TNFα) production in human whole blood. Compared to apremilast, another PDE4 inhibitor, PALI-0008 showed approximately 20 times higher potency in reducing TNFα production.
The company's Chief Medical Officer, Dr. Mitch Jones, highlighted that the targeted activation of PALI-2108 primarily in the colon could minimize systemic exposure and potential side effects. This feature addresses common toxicity issues associated with other PDE4 inhibitors.
A microbiome study also supported the activation mechanism of PALI-2108, revealing consistent levels of the beta-glucuronidase enzyme necessary for its activation across different species, including mice, dogs, healthy humans, and UC patients.
Palisade Bio plans to initiate a Phase 1 clinical study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in healthy volunteers and an open-label study involving UC patients before the end of the year.
The company is dedicated to developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, aiming to transform the treatment landscape with targeted approaches. Palisade Bio's progress with PALI-2108 is based on a press release statement and represents a step towards addressing the unmet needs in IBD treatment.
In other recent news, Palisade Bio, Inc. has made significant strides in advancing its ulcerative colitis treatment, PALI-2108. The biopharmaceutical company has received approval from Health Canada to commence a Phase 1 clinical trial for PALI-2108, a drug candidate for ulcerative colitis. This trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in healthy volunteers and patients suffering from ulcerative colitis.
In parallel, Palisade Bio has refined its patient selection strategies for PALI-2108 in collaboration with Strand Life Sciences, enhancing the precision of treatment for ulcerative colitis. The company has also updated its employment agreement with CEO J.D. Finley, outlining potential severance benefits and conditions for stock option grants.
In terms of financial developments, analysts from Ladenburg Thalmann have maintained a Buy rating for Palisade Bio. Furthermore, the company's shareholders recently elected three directors and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm. These are among the recent developments within the company.
InvestingPro Insights
As Palisade Bio (NASDAQ: PALI) advances its promising PALI-2108 drug for ulcerative colitis treatment, investors should consider some key financial metrics and insights from InvestingPro.
According to InvestingPro data, Palisade Bio's market capitalization stands at a modest $3.67 million, reflecting its early-stage status in drug development. The company's price-to-book ratio of 0.37 suggests that the stock might be undervalued relative to its book value, which could be of interest to value-oriented investors considering the potential of PALI-2108.
However, it's crucial to note that Palisade Bio is currently not profitable, with a negative operating income of $14.59 million over the last twelve months as of Q2 2024. This aligns with the company's focus on research and development, typical for biopharmaceutical firms in the pre-revenue stage.
InvestingPro Tips highlight that Palisade Bio holds more cash than debt on its balance sheet, which is a positive sign for a company investing heavily in drug development. This financial cushion could provide some runway as the company progresses towards clinical trials for PALI-2108.
Another InvestingPro Tip indicates that analysts anticipate sales growth in the current year, which could be linked to the potential commercialization of PALI-2108 if clinical trials prove successful. However, investors should be aware that the company is quickly burning through cash, a common characteristic of biotech firms in the development phase.
For those interested in a deeper analysis, InvestingPro offers 12 additional tips for Palisade Bio, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.